This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Sarpogrelate
Accession Number
DB12163
Type
Small Molecule
Groups
Investigational
Description

Sarpogrelate has been investigated for the treatment of Diabetes Mellitus, Diabetic Nephropathy, Coronary Artery Disease, and Renal Insufficiency, Chronic.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Sarpogrelate HydrochlorideFQN8N8QP1B135159-51-2POQBIDFFYCYHOB-UHFFFAOYSA-N
Categories
UNII
19P708E787
CAS number
125926-17-2
Weight
Average: 429.513
Monoisotopic: 429.215137722
Chemical Formula
C24H31NO6
InChI Key
FFYNAVGJSYHHFO-UHFFFAOYSA-N
InChI
InChI=1S/C24H31NO6/c1-25(2)16-21(31-24(28)14-13-23(26)27)17-30-22-10-5-4-8-19(22)12-11-18-7-6-9-20(15-18)29-3/h4-10,15,21H,11-14,16-17H2,1-3H3,(H,26,27)
IUPAC Name
4-{[1-(dimethylamino)-3-{2-[2-(3-methoxyphenyl)ethyl]phenoxy}propan-2-yl]oxy}-4-oxobutanoic acid
SMILES
COC1=CC(CCC2=CC=CC=C2OCC(CN(C)C)OC(=O)CCC(O)=O)=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2CNot AvailableHuman
U5-hydroxytryptamine receptor 2A
inverse agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabSarpogrelate may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolSarpogrelate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
AlteplaseSarpogrelate may increase the anticoagulant activities of Alteplase.Approved
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Sarpogrelate.Approved, Investigational, Vet Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Aminosalicylic Acid.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Sarpogrelate.Approved
AncrodSarpogrelate may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Sarpogrelate.Investigational
AnistreplaseSarpogrelate may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanSarpogrelate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Apixaban.Approved
AprotininThe therapeutic efficacy of Sarpogrelate can be decreased when used in combination with Aprotinin.Approved, Investigational, Withdrawn
ArdeparinSarpogrelate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanSarpogrelate may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinSarpogrelate may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the anticoagulant activities of Sarpogrelate.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Balsalazide.Approved, Investigational
BatroxobinSarpogrelate may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminSarpogrelate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinSarpogrelate may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Sarpogrelate.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Sarpogrelate.Approved
BeraprostBeraprost may increase the anticoagulant activities of Sarpogrelate.Investigational
BivalirudinSarpogrelate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseSarpogrelate may increase the anticoagulant activities of Brinase.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Sarpogrelate.Experimental
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Sarpogrelate.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Sarpogrelate.Investigational
CangrelorCangrelor may increase the anticoagulant activities of Sarpogrelate.Approved
CaplacizumabSarpogrelate may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinSarpogrelate may increase the anticoagulant activities of Certoparin.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sarpogrelate.Approved
CilostazolCilostazol may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Sarpogrelate.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Sarpogrelate.Approved, Vet Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Sarpogrelate.Approved
CloricromenSarpogrelate may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneSarpogrelate may increase the anticoagulant activities of Clorindione.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sarpogrelate.Approved, Illicit
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Collagenase clostridium histolyticum.Approved, Investigational
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sarpogrelate.Approved
Dabigatran etexilateSarpogrelate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinSarpogrelate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSarpogrelate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanSarpogrelate may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Dersalazine.Investigational
DesirudinSarpogrelate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseSarpogrelate may increase the anticoagulant activities of Desmoteplase.Investigational
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sarpogrelate.Approved
DextranSarpogrelate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolSarpogrelate may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Diflunisal.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sarpogrelate.Approved
DiphenadioneSarpogrelate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Sarpogrelate.Approved
DitazoleSarpogrelate may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DotarizineThe risk or severity of adverse effects can be increased when Dotarizine is combined with Sarpogrelate.Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate.Approved, Vet Approved
Drotrecogin alfaSarpogrelate may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidSarpogrelate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSarpogrelate may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinSarpogrelate may increase the anticoagulant activities of Enoxaparin.Approved
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Sarpogrelate.Approved, Investigational
EpinastineEpinastine may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
EplivanserinSarpogrelate may increase the anticoagulant activities of Eplivanserin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Sarpogrelate.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
EthanolSarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sarpogrelate.Approved
Ethyl biscoumacetateSarpogrelate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sarpogrelate.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sarpogrelate.Approved, Illicit, Investigational, Vet Approved
Ferulic acidSarpogrelate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinSarpogrelate may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneSarpogrelate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Sarpogrelate.Approved
FluoxetineFluoxetine may increase the antiplatelet activities of Sarpogrelate.Approved, Vet Approved
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Sarpogrelate.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Sarpogrelate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Fluvoxamine.Approved, Investigational
FondaparinuxSarpogrelate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sarpogrelate.Approved, Investigational
GabexateSarpogrelate may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Sarpogrelate.Approved, Investigational
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Hemoglobin crosfumaril.Experimental
HeparinSarpogrelate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineSarpogrelate may increase the anticoagulant activities of Higenamine.Investigational
HydrocodoneSarpogrelate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Sarpogrelate.Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sarpogrelate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sarpogrelate.Approved
IbudilastIbudilast may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational, Nutraceutical
IdraparinuxSarpogrelate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Sarpogrelate.Investigational
IloprostIloprost may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
IndobufenSarpogrelate may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the anticoagulant activities of Sarpogrelate.Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Sarpogrelate.Approved, Investigational
LepirudinSarpogrelate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanSarpogrelate may increase the anticoagulant activities of Letaxaban.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Sarpogrelate.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Sarpogrelate.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Sarpogrelate.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Sarpogrelate.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Sarpogrelate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Magnesium citrate is combined with Sarpogrelate.Approved
Magnesium sulfateThe therapeutic efficacy of Sarpogrelate can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Sarpogrelate.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Sarpogrelate.Approved
MelagatranSarpogrelate may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Mesalazine.Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sarpogrelate.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the anticoagulant activities of Sarpogrelate.Approved
NadroparinSarpogrelate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatSarpogrelate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the antiplatelet activities of Sarpogrelate.Investigational
NimesulideNimesulide may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Sarpogrelate.Approved, Nutraceutical
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Sarpogrelate.Approved
OtamixabanSarpogrelate may increase the anticoagulant activities of Otamixaban.Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sarpogrelate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sarpogrelate.Approved, Investigational, Vet Approved
OzagrelSarpogrelate may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinSarpogrelate may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Sarpogrelate.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Sarpogrelate.Experimental
Pentaerythritol TetranitrateSarpogrelate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sarpogrelate.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
PhenindioneSarpogrelate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Sarpogrelate.Approved, Investigational
PhenprocoumonSarpogrelate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Phenyl aminosalicylate.Approved
PicotamideSarpogrelate may increase the anticoagulant activities of Picotamide.Experimental
Potassium CitrateSarpogrelate may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PramipexoleSarpogrelate may increase the sedative activities of Pramipexole.Approved, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Sarpogrelate.Approved
PregabalinThe therapeutic efficacy of Sarpogrelate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sarpogrelate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Sarpogrelate.Approved, Investigational
Protein CSarpogrelate may increase the anticoagulant activities of Protein C.Approved
Protein S humanSarpogrelate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSarpogrelate may increase the anticoagulant activities of Protocatechualdehyde.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Pseudoephedrine.Approved
PyrantelThe risk or severity of adverse effects can be increased when Pyrantel is combined with Sarpogrelate.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Sarpogrelate.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Sarpogrelate.Investigational
RelcovaptanRelcovaptan may increase the anticoagulant activities of Sarpogrelate.Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Sarpogrelate.Approved, Experimental, Investigational
ReteplaseSarpogrelate may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinSarpogrelate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Sarpogrelate.Approved
RivaroxabanSarpogrelate may increase the anticoagulant activities of Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sarpogrelate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Salicylic acid.Approved, Investigational, Vet Approved
SaruplaseSarpogrelate may increase the anticoagulant activities of Saruplase.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sarpogrelate.Approved, Investigational
SelexipagSarpogrelate may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the anticoagulant activities of Sarpogrelate.Approved, Vet Approved
Sodium CitrateThe risk or severity of bleeding can be increased when Sarpogrelate is combined with Sodium Citrate.Approved, Investigational
SRT501SRT501 may increase the anticoagulant activities of Sarpogrelate.Investigational
StreptokinaseSarpogrelate may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Sulfasalazine.Approved
SulodexideSarpogrelate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sarpogrelate.Approved, Investigational
TenecteplaseSarpogrelate may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Sarpogrelate.Investigational
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Sarpogrelate.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Sarpogrelate.Investigational
TicagrelorSarpogrelate may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Sarpogrelate.Approved
TinzaparinSarpogrelate may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolSarpogrelate may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Sarpogrelate.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Sarpogrelate.Approved
TositumomabThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Tositumomab.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sarpogrelate.Approved, Investigational
TranilastTranilast may increase the antiplatelet activities of Sarpogrelate.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Sarpogrelate.Approved
TreprostinilSarpogrelate may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalTriflusal may increase the anticoagulant activities of Sarpogrelate.Approved, Investigational
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Sarpogrelate.Approved
Trolamine salicylateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Trolamine salicylate.Approved
TroxerutinSarpogrelate may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseSarpogrelate may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Sarpogrelate.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sarpogrelate.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Sarpogrelate.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Sarpogrelate.Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Sarpogrelate.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Sarpogrelate.Approved
WarfarinSarpogrelate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSarpogrelate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sarpogrelate.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sarpogrelate.Approved, Investigational
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sarpogrelate.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5160
PubChem Substance
347828455
ChemSpider
4976
BindingDB
50093789
ChEBI
135697
ChEMBL
CHEMBL52939
Wikipedia
Sarpogrelate

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHigh Blood Pressure (Hypertension) / Peripheral Artery Disease (PAD)1
3CompletedPreventionCerebral Infarctions1
3CompletedTreatmentCoronary Artery Disease / Diabetes Mellitus (DM) / Renal Insufficiency,Chronic1
4CompletedTreatmentCoronary Artery Disease1
4RecruitingTreatmentAngina, Prinzmetal's1
4Unknown StatusPreventionChronic Kidney Disease (CKD)1
4Unknown StatusTreatmentDiabetic Nephropathies1
Not AvailableUnknown StatusTreatmentAtherosclerosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0109 mg/mLALOGPS
logP3.57ALOGPS
logP1.12ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)8.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area85.3 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity117.35 m3·mol-1ChemAxon
Polarizability46.89 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Stilbenes
Sub Class
Not Available
Direct Parent
Stilbenes
Alternative Parents
Phenoxy compounds / Methoxybenzenes / Anisoles / Fatty acid esters / Alkyl aryl ethers / Dicarboxylic acids and derivatives / Trialkylamines / Carboxylic acid esters / Amino acids / Carboxylic acids
show 4 more
Substituents
Stilbene / Phenoxy compound / Anisole / Methoxybenzene / Phenol ether / Alkyl aryl ether / Fatty acid ester / Monocyclic benzene moiety / Fatty acyl / Benzenoid
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Muntasir HA, Takahashi J, Rashid M, Ahmed M, Komiyama T, Hossain M, Kawakami J, Nashimoto M, Nagatomo T: Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding. Biol Pharm Bull. 2006 Aug;29(8):1645-50. [PubMed:16880620]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Muntasir HA, Bhuiyan MA, Ishiguro M, Ozaki M, Nagatomo T: Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. J Pharmacol Sci. 2006 Oct;102(2):189-95. Epub 2006 Oct 7. [PubMed:17031071]
  2. Aly SA, Hossain M, Bhuiyan MA, Nakamura T, Nagatomo T: Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate. J Pharmacol Sci. 2009 Aug;110(4):445-50. [PubMed:19672037]

Drug created on October 20, 2016 15:30 / Updated on August 02, 2018 06:34